The Motley Fool

The GlaxoSmithKline share price is up 7% this week. Here are five reasons why!

Image source: Getty Images.

Keen Fool readers will know that I’m a fan of UK pharmaceuticals giant GlaxoSmithKline (LSE: GSK). Of all the FTSE 100 stocks I’ve written about since March, the GlaxoSmithKline share price has been #1 on my mind.

The GSK share price’s fall and rise

I’ve just returned from a three-week UK staycation, during which the GlaxoSmithKline share price has declined persistently. Before I went away, GSK shares closed at nearly 1,612p on 12 August. Last Friday, they finished at 1,430p, down 182p (11.3%) in two-and-a-half weeks. That’s a pretty steep decline for a ‘boring’ value share.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

However, GSK shares have staged a big comeback this week. As I write, they trade above 1,532p, which is a 7.1% leap halfway into this week. Here are five reasons why I think this comeback was on the cards and what I’d do now.

1. The share price went too low

At last Friday’s 1,430p, GSK shares stood just 55p above their 2020 low of 1,375p set on on 23 March during the Covid-19 market meltdown. Clearly, some investors decided that the GlaxoSmithKline share price had declined too far. Hence, they piled into the shares, making GSK one of this week’s most-traded UK shares.

2. GSK shares became too cheap

Based on diluted earnings per share of 92.6p in 2019 and last Friday’s share price of 1,430p, GSK trades on a price-to-earnings ratio of 14.4. This is low for GSK shares in historical terms, hence their increased attractiveness to value investors.

3. The dividend yield had soared to 5.6%

For the past five years, GSK shares have paid a yearly dividend of 80p (plus a 20p special dividend for 2015). An 80p cash payout based on Friday’s closing price of 1,430p gives a dividend yield of 5.6%. That’s mouthwatering to value investors, hence the shift from sellers to buyers this week.

4. Tech shares took a tumble

The past few days have seen US tech shares stumble and then tumble. Shares in Apple have dived from nearly $138 to below $113 in a week. Meanwhile, Tesla‘s stock price has crashed by a third, from $500 to $330 in five trading sessions.

With tech shares sliding, a fair few fund managers and individual investors will have retreated from the FAANG bubble to buy value-oriented shares. Of course, a rotation into value shares would likely help to push up the GlaxoSmithKline share price.

5. GSK’s Covid-19 vaccine is progressing

Working with Sanofi, GSK is developing a vaccine against Covid-19. According to the latest news, the trial is going well. This week, GSK’s big rival AstraZeneca temporarily halted its vaccine trial after an adverse reaction. Hence, disappointed investors may well have sold Astra shares to buy into GSK, thus lifting the GSK share price.

To summarise, the GlaxoSmithKline share price has leapt this week, driven by higher share volumes and more investors hitting the ‘Buy’ button. However, I still see GSK shares as offering compelling long-term value, so I would keep buying them today!

A Top Share with Enormous Growth Potential

Savvy investors like you won’t want to miss out on this timely opportunity…

Here’s your chance to discover exactly what has got our Motley Fool UK analyst all fired up about this ‘pure-play’ online business (yes, despite the pandemic!).

Not only does this company enjoy a dominant market-leading position…

But its capital-light, highly scalable business model has previously helped it deliver consistently high sales, astounding near-70% margins, and rising shareholder returns … in fact, in 2019 it returned a whopping £150m+ to shareholders in dividends and buybacks!

And here’s the really exciting part…

While COVID-19 may have thrown the company a curveball, management have acted swiftly to ensure this business is as well placed as it can be to ride out the current period of uncertainty… in fact, our analyst believes it should come roaring back to life, just as soon as normal economic activity resumes.

That’s why we think now could be the perfect time for you to start building your own stake in this exceptional business – especially given the shares look to be trading on a fairly undemanding valuation for the year to March 2021.

Click here to claim your copy of this special report now — and we’ll tell you the name of this Top Growth Share… free of charge!

Cliffdarcy owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.